AKT1 and colorectal carcinoma: To study the underlying mechanism of GRP94 in CRC, we further treated the DLD-1 cells with ERK, JNK and Akt/p38 specific kinase inhibitors, pd98059, sp600125, and sb203580 respectively and checked ETV1 expression.